Rheumatoid Arthritis - Anti-TNF

International Immunopharmacology

Volumn 27, Issue 2, 2015, Pages 180-184

  Chaabo, Khaldoun ^a   Kirkham, Bruce ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Review; Rheumatoid arthritis; TNF; TNF inhibitors

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; LIPID; METHOTREXATE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIPID BLOOD LEVEL; LONG TERM CARE; META ANALYSIS (TOPIC); OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; IMMUNOLOGY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937161948     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.04.051     Document Type: Article

References (54)

1. B.B. Aggarwal, S.C. Gupta, and J.H. Kim Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey Blood 119 3 Jan 19, 2012 651 665
2. O'Malley Action of bacterial polysaccharide on tumors: II. Damage of Sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance J. Natl. Cancer Inst. 29 1962 1169 1175
3. E.A. Carswell, L.J. Old, R.L. Kassel, S. Green, N. Fiore, and B. Williamson An endotoxin-induced serum factor that causes necrosis of tumors Proc. Natl. Acad. Sci. U. S. A. 72 9 1975 3666 3670
4. D. Pennica, G.E. Nedwin, J.S. Hayflick, P.H. Seeburg, R. Derynck, M.A. Palladino, W.J. Kohr, Aggarwal, and Goeddel Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin Nature 312 5996 1984 724 729
5. B.B. Aggarwal, W.J. Kohr, P.E. Hass, and et al. Human tumor necrosis factor: production, purification, and characterization J. Biol. Chem. 260 4 1985 2345 2354
6. M.J. Elliott, R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, P. Katsikis, and et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha Arthritis Rheum. 36 1993 1681 1690
7. M.J. Elliott, R.N. Maini, M. Feldmann, J.R. Kalden, C. Antoni, J.S. Smolen, B. Leeb, F.C. Breedveld, J.D. Macfarlane, H. Bijl, and et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
8. R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group Lancet 354 1999 1932 1939
9. L.W. Moreland, S.W. Baumgartner, M.H. Schiff, E.A. Tindall, R.M. Fleischmann, A.L. Weaver, and et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein N. Engl. J. Med. 337 1997 141 147
10. L.W. Moreland, M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, K.J. Bulpitt, and et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial Ann. Intern. Med. 130 1999 478 486
11. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, and et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate N. Engl. J. Med. 340 1999 253 259
12. J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, E.C. Keystone, and et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N. Engl. J. Med. 343 2000 1586 1593
13. R. Westhovens, D. Yocum, J. Han, A. Berman, I. Strusberg, P. Geusens, and M.U. Rahman The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial Arthritis Rheum. 54 2006 1075 1086
14. M.H. Schiff, G.R. Burmester, J.D. Kent, A.L. Pangan, H. Kupper, S.B. Fitzpatrick, and C. Donovan Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis Ann. Rheum. Dis. 65 2006 889 894
15. F. Wolfe, and K. Michaud Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study Arthritis Rheum. 56 2007 2886 2895
16. L.T.H. Jacobsson, C. Turesson, J.-A. Nilsson, I.F. Petersson, E. Lindqvist, T. Saxne, and P. Geborek Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis Ann. Rheum. Dis. 66 2007 670 675
17. W.G. Dixon, K. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, D.P. Symmons, and British Society for Rheumatology Biologics Register Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Arthritis Rheum. 54 8 Aug 2006 2368 2376
18. S. Ramiro, C. Gaujoux-Viala, J.L. Nam, J.S. Smolen, M. Buch, L. Gossec, D. van der Heijde, K. Winthrop, and R. Landewé Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis Ann. Rheum. Dis. 73 3 Mar 2014 529 535
19. K.L. Winthrop, J.W. Baddley, L. Chen, L. Liu, C.G. Grijalva, E. Delzell, T. Beukelman, N.M. Patkar, F. Xie, K.G. Saag, L.J. Herrinton, D.H. Solomon, J.D. Lewis, and J.R. Curtis Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster JAMA 309 9 Mar 6, 2013 887 895
20. M. Wong, S.P. Oakley, L. Young, B.Y. Jiang, A. Wierzbicki, G. Panayi, P. Chowienczyk, and B. Kirkham Infliximab improves vascular stiffness in patients with rheumatoid arthritis Ann. Rheum. Dis. 68 2009 1277 1284
21. L.S. Tam, G.D. Kitas, and M.A. González-Gay Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 53 6 Jun 2014 1108 1119
22. B.W. Kirkham, M.C. Wasko, E.C. Hsia, R.M. Fleischmann, M.C. Genovese, E.L. Matteson, H. Liu, and M.U. Rahman Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation Ann. Rheum. Dis. 73 2014 161 169
23. D.H. Solomon, J.R. Curtis, K.G. Saag, J. Lii, L. Chen, L.R. Harrold, L.J. Herrinton, D.J. Graham, M.K. Kowal, B. Kuriya, L. Liu, M.R. Griffin, J.D. Lewis, and J.A. Rassen Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs Am. J. Med. 126 8 Aug 2013 730.e9 730.e17
24. D.H. Solomon, J.A. Rassen, B. Kuriya, L. Chen, L.R. Harrold, D.J. Graham, J.D. Lewis, J. Lii, L. Liu, M.R. Griffin, and J.R. Curtis Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist Ann. Rheum. Dis. 72 11 Nov 2013 1813 1818
25. J.S. Smolen, R. Landewe, F.C. Breedveld, and et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann. Rheum. Dis. 73 2014 492 509
26. J.A. Singh, D.E. Furst, A. Bharat, and et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res. (Hoboken) 64 2012 625 639
27. A. Kavanaugh, S.J. Lee, J.R. Curtis, J.D. Greenberg, and et al. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry Ann. Rheum. Dis. Dec 3, 2014 10.1136/annrheumdis-2014-206435 (pii: annrheumdis-2014-206435. [Epub ahead of print)
28. K. Yoshida, Y.K. Sung, A. Kavanaugh, and et al. Biologic discontinuation studies: a systematic review of methods Ann. Rheum. Dis. 73 2014 595 599
29. Y. Tanaka, T. Takeuchi, T. Mimori, and et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. RRR study investigators Ann. Rheum. Dis. 69 7 Jul 2010 1286 1291
30. J.S. Smolen, P. Nash, P. Durez, and et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial Lancet 381 2013 918 929
31. J.S. Smolen, P. Emery, G.F. Ferraccioli, and et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the CERTAIN study Ann. Rheum. Dis. 71 Suppl. 3 2012 361
32. Y. Tanaka, S. Hirata, S. Kubo, and et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study Nov 28, 2013 (doi: 10.1136)
33. J.S. Smolen, P. Emery, R. Fleischmann, and et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial Lancet 383 9914 Jan 25, 2014 321 332
34. J. Detert, H. Bastian, J. Listing, and et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study Ann. Rheum. Dis. 72 2013 844 850
35. P. Emery, M. Hammoudeh, O. FitzGerald, and et al. Sustained remission with etanercept tapering in early rheumatoid arthritis N. Engl. J. Med. 371 19 Nov 6, 2014 1781 1792
36. J.L. Nam, E. Villeneuve, E.M. Hensor, and et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study) Ann. Rheum. Dis. 73 1 Jan 2014 75 85 (doi: 10.1136)
37. M. Van Den Broek, W.F. Lems, and C.F. Allaart Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin. Exp. Rheumatol. 30 Suppl. 73 2012 S21 S26
38. J. Swierkot, K. Bogunia-Kubik, B. Nowak, K. Bialowas, L. Korman, K. Gebura, K. Kolossa, S. Jeka, and P. Wiland Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis Joint Bone Spine 82 2 Mar 2015 94 99
39. J.S. Chen, J. Makovey, M. Lassere, R. Buchbinder, and L.M. March Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis Arthritis Care Res. (Hoboken) 66 3 Mar 2014 464 472
40. K.L. Hyrich, M. Lunt, K.D. Watson, and et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum. 56 2007 13 20
41. S.N. Nikas, P.V. Voulgari, Y. Alamanos, and et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study Ann. Rheum. Dis. 65 2006 257 260
42. J.A. Gomez-Puerta, R. Sanmarti, J.R. Rodriguez-Cros, and et al. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy Ann. Rheum. Dis. 63 2004 896
43. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, and T. Saxne Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab Arthritis Rheum. 54 2006 3782 3789
44. G.J. Wolbink, A.E. Voskuyl, W.F. Lems, de GE, M.T. Nurmohamed, P.P. Tak, B.A. Dijkmans, and L. Aarden Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis Ann. Rheum. Dis. 64 2005 704 707
45. G.J. Wolbink, M. Vis, W. Lems, A.E. Voskuyl, de GE, M.T. Nurmohamed, S. Stapel, P.P. Tak, L. Aarden, and B. Dijkmans Development of anti infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis Arthritis Rheum. 54 2006 711 715
46. P.A. van Schouwenburg, T. Rispens, and G.J. Wolbink Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis Nat. Rev. Rheumatol. 9 3 Mar 2013 164 172
47. R.K. Dore, and et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis Clin. Exp. Rheumatol. 25 2007 40 46
48. A. Jamnitski, and et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients Ann. Rheum. Dis. 71 2012 88 91
49. P.J. Anderson Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles Semin. Arthritis Rheum. 34 2005 19 22
50. G.M. Bartelds, and et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study Arthritis Res. Ther. 12 2010 R221
51. R.N. Maini, and et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum. 41 1998 1552 1563
52. N. Emi Aikawa, J.F. de Carvalho, C. Artur Almeida Silva, and E. Bonfá Immunogenicity of anti-TNF-alpha agents in autoimmune diseases Clin. Rev. Allergy Immunol. 38 2-3 Apr 2010 82 89
53. C.L. Krieckaert, G.M. Bartelds, W.F. Lems, and G.J. Wolbink The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review Arthritis Res. Ther. 12 2010 217
54. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, and et al. Antiadalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms Arthritis Rheum. 60 2009 2541 2542